分上下午两场 现场气氛轻松

Core Points - The negotiation for the 2025 National Medical Insurance Catalog and commercial insurance innovative drug pricing has officially started in Beijing, lasting 4 to 5 days [1] - The first day of negotiations included both cataloged and non-cataloged drugs, with some non-cataloged drugs applying for both basic medical insurance and commercial insurance innovative drug catalogs [1][4] - Numerous companies are involved in the negotiations, with representatives attending multiple sessions throughout the day [2][4] Group 1: Negotiation Details - The negotiations began at 8:30 AM, with representatives arriving early, indicating high participation [2] - The atmosphere during the negotiations was described as relaxed, with representatives discussing market conditions and the weather [3][4] - The first day saw participation from both foreign and domestic pharmaceutical companies, including major players like Pfizer and AstraZeneca [4] Group 2: Drug Listings and Financial Data - A total of 535 drugs passed the formal review for the basic medical insurance catalog, with over 300 being non-cataloged drugs [5] - Additionally, 121 high-value drugs were approved for the commercial insurance innovative drug catalog [5] - From January to August 2025, the total income for basic medical insurance (including maternity insurance) was approximately 1,880.99 billion yuan, while expenditures were around 1,543.22 billion yuan, indicating stable fund operations [5][6]